Biblio
19 Annual Meeting of the Safety Pharmacology Society: regulatory and safety perspectives for advanced therapy medicinal products (cellular and gene therapy products). Expert Opin Drug Saf. 2020.
. Agonistic and antagonistic roles of fibroblasts and cardiomyocytes on viscoelastic stiffening of engineered human myocardium. Prog Biophys Mol Biol. 2018.
. Cardiac Engraftment of Genetically-Selected Parthenogenetic Stem Cell-Derived Cardiomyocytes. PLoS One. 2015;10(6):e0131511.
. Challenges to Heart Repair with Pluripotent Stem Cell-Derived Cardiomyocytes. Trends Cardiovasc Med. 2020.
. Drug testing in human-induced pluripotent stem cell-derived cardiomyocytes from a patient with short QT syndrome type 1. Clin Pharmacol Ther. 2019.
Establishment of a second generation homozygous CRISPRa human induced pluripotent stem cell (hiPSC) line for enhanced levels of endogenous gene activation. Stem Cell Res. 2021;56:102518.
. Establishment of two homozygous CRISPR interference (CRISPRi) knock-in human induced pluripotent stem cell (hiPSC) lines for titratable endogenous gene repression. Stem Cell Res. 2021;55:102473.
. Generation of homozygous CRISPRa human induced pluripotent stem cell (hiPSC) lines for sustained endogenous gene activation. Stem Cell Res. 2020;48:101944.
. Genome engineering of a neuronal specific, optogenetic, induced pluripotent stem cell line. Stem Cell Res. 2024;75:103317.
. Preclinical evaluation of CRISPR-based therapies for Noonan syndrome caused by deep-intronic variants. Mol Ther Nucleic Acids. 2024;35(1):102123.
. Protocol to develop force-generating human skeletal muscle organoids. STAR Protoc. 2023;5(1):102794.
. .